[1] Zhao H, Wang Q, Luo C, et al. Recompensation of decompensated hepatitis B cirrhosis: Current status and challenges. Biomed Res Int, 2020, 2020:9609731. [2] Xu B, Liu A, Liu Y, et al. Correlations between serum hepatitis B core-related antigen and hepatitis B surface antigen in patients with hepatitis B cirrhosis and a hepatitis B virus-DNA-negative status: a retrospective study. J Int Med Res, 2022, 50(10):3000605221130714. [3] Liao Z, Wang Z, Su C, et al.Long term prophylactic anticoagulation for portal vein thrombosis after splenectomy: A systematic review and meta-analysis. PLoS One, 2023, 18(8):e0290164. [4] Zhang DQ, Mu YP, Xu Y, et al. Research progress in Chinese medicine preparations for promoting blood circulation and removing blood stasis for cirrhotic patients with portal vein thrombosis following splenectomy. Chin J Integr Med, 2022, 28(9):855-863. [5] Katano K, Nakanuma S, Araki T, et al. Predictors of portal vein thrombosis after simultaneous hepatectomy and splenectomy: A single-center retrospective study. Asian J Surg, 2024, 47(12):5137-5142. [6] Li Y, Fu X, Li Y, et al. Early prevention and risk factors analysis of portal vein system thrombosis after laparoscopic splenectomy and pericardial devascularization. Surg Endosc, 2022, 36(12):8918-8926. [7] Zhang Y, Xu BY, Wang XB, et al. Prevalence and clinical significance of portal vein thrombosis in patients with cirrhosis and acute decompensation. Clin Gastroenterol Hepatol, 2020, 18(11):2564-2572,e1. [8] 中国医师协会感染科医师分会, 国家感染性疾病临床医学研究中心. 乙型肝炎全人群管理专家共识(2023年). 中华临床感染病杂志, 2024, 17(1):1-13. [9] Mao W, Fan Y, Wang X, et al. Phloretin ameliorates diabetes-induced endothelial injury through AMPK-dependent anti-end MT pathway. Pharmacol Res, 2022, 179:106205. [10] An Y, Geng K, WangHY, et al. Hyperglycemia-induced STING signaling activation leads to aortic endothelial injury in diabetes. Cell Commun Signal, 2023, 21(1):365. [11] Larrue H, D'Amico G, Olivas P, et al. TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis. J Hepatol, 2023, 79(3):692-703. [12] Tonon M, D'Ambrosio R, Calvino V, et al. A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis. J Hepatol, 2024, 80(4):603-609. [13] Dong G, Huang XQ, Zhu YL, et al. Increased portal vein diameter is predictive of portal vein thrombosis development in patients with liver cirrhosis. Ann Transl Med, 2021, 9(4):289. [14] 司同, 朱家宝, 吴彬彬. 超声联合剪切波弹性成像评估肝硬化门脉高压症患者并发高风险食管静脉曲张价值分析. 实用肝脏病杂志, 2025, 28(1):100-103. [15] Lin YK, Cai XR, Hong HJ, et al. Risk factors of portal vein system thrombosis after splenectomy: a meta-analysis. ANZ J Surg, 2023, 93(12):2806-2819. [16] Han JB, Shu QH, Yi YX, et al. Predictors of long-term rebleeding riskin cirrhotic patients undergoing esophagogastric devascularization and splenectomy: Impact of portal vein thrombosis and hemoglobin levels. Med Sci Monit, 2023, 29:e941153. [17] O'Leary JG, Greenberg CS, Patton HM, et al. AGA clinical practice update: Coagulation in cirrhosis. Gastroenterology, 2019, 157(1):34-43,e1. [18] Colli A, Gana JC, Yap J, et al. Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal veinthrombosis. Cochrane Database Syst Rev, 2017, 4(4):CD008759. [19] Wu Q, Zhang X, Xu A, et al. Efficacy and safety of anticoagulation in asymptomatic cirrhotic patients with portal vein thrombosis: a systematic review and meta-analysis. Scand J Gastroenterol, 2025, 60(2):197-207. [20] 宋子敏, 徐锋, 杨纯博, 等. 肝硬化门静脉高压症脾切除术后门静脉系统血栓形成相关因素分析. 中华普通外科学文献(电子版), 2020, 14(3):184-188. |